Press Release: Aqualung Therapeutics : Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its ...

(PR-inside.com) Aqualung has selected Novotech as their CRO partner to conduct the P2a PUERTA study in moderate/severe ARDS subjects.Expected screening for enrolled subjects to begin April/May 2023.Aqualung Submitting an end of P1 (EOP1) meeting data packet to the FDA in February based on preliminary results of the P1a Healthy Human Volunteer study.TUCSON, AZ / ACESSWIRE / January 31, 2023 / Aqualung Therapeutics, an early stage immunotherapeutics company with a novel anti-inflammatory and anti-fibrotic therapeutic platform for life-threatening unchecked inflammation/fibrosis, today announced that it has engaged Novotech, a leading Asia Pacific centered, full-service contract research organization ("CRO") in the Asia-Pacific, United States ..